Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells

Autor(es):Mostrar menos -

Freitas, Rosana Aparecida ^[1] ; Silva dos Santos, Guilherme Augusto ^[1] ; Gimenes Teixeira, Hamilton Luiz ^[1] ; Scheucher, Priscila Santos ^[1] ; Lucena-Araujo, Antonio Roberto ^[1] ; Gouveia Lima, Ana Silvia ^[1] ; Abreu e Lima, Rodrigo Siqueira ^[1] ; Garcia, Aglair Bergamo ^[1] ; Jordao, Jr., Alceu Afonso ^[2] ; Faicao, Roberto Passetto ^[1] ; Vannucchi, Helio ^[2] ; Rego, Eduardo Magalhaes ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Div Hematol, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Div Nutr, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049900 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Leukemia Research; v. 33, n. 7, p. 958-963, JUL 2009.
• Citações Web of Science: 6

Resumo

We analyzed the effect of (+)alpha-tocopheryl succinate (alpha-TOS) alone or associated with arsenic trioxide (ATO) or all-trans retinoid acid (ATRA) in acute promyelocytic leukemia (APL). alpha-TOS-induced apoptosis in APL clinical samples and in ATRA-sensitive (NB4) and ATRA-resistant (NB4-R2) APL cell lines. The effective dose 50% (ED-50) was calculated to be 71 and 58 mu M, for NB4 and NB4-R2, respectively. a-TOS neither induced nor modified ATRA-induced differentiation of APL cells, and did not affect the proliferation and differentiation of normal CD34(+) hematopoietic progenitors in methylcellulose assays. alpha-TOS exerted a moderate antagonistic effect to ATO-induced apoptosis when treatment was done simultaneously but when alpha-TOS was added 24 h after ATO, an additive effect was observed. Our results support the concept of alpha-TOS as an anti-leukemic compound which spares normal hematopoiesis. (C) 2008 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 01/12406-4 - Avaliacao do efeito da vitamina e sobre a apoptose em celulas da leucemia promielocitica aguda.
• Beneficiário: Rosana Aparecida de Freitas
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 98/14247-6 - Center for Research on Cell-Based Therapy
• Beneficiário: Marco Antonio Zago
• Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs